Vittoria Perano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Vittoria Perano has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
Alberto Mantovani
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
1 shared publicationAlex Kartheuser
Colorectal Surgery Unit, University Hospital Saint-Luc , Brussels
1 shared publication- Andrea Pansa
Upper Gastrointestinal Surgery Unit, IRCCS Humanitas Research Hospital, Milan, Italy
1 shared publication Angela Palmisano
Division of Hepatobiliary and General Surgery, Department of Surgery, IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy
1 shared publicationAnjelli Wignakumar
Ellen Leifer Shulman and Steven Shulman Digestive Disease Centre, Cleveland Clinic Florida , Weston, Florida
1 shared publication- Antonino Spinelli
Division of Colon and Rectal Surgery, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
1 shared publication
Latest Publications
- 1 September 2026
- Published by Edizioni Minerva Medica in Minerva Surgery
- Vol. 81 (3)
Hybrid-energy-based devices in thyroid surgery: a comparative study on surgical timing and clinical outcomes
- 1 September 2026
- Published by Edizioni Minerva Medica in Minerva Surgery
- Vol. 81 (3)
Hybrid-energy-based devices in thyroid surgery: a comparative study on surgical timing and clinical outcomes
- Open Access
- 29 November 2025
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 112 (12)
Global benchmarks for minimally invasive right hemicolectomy for cancer
- 29 November 2025
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 112 (12)
Open AccessGlobal benchmarks for minimally invasive right hemicolectomy for cancer
- 8 August 2025
- Published by Wolters Kluwer Health in Annals of Surgery
From Cherry Picking to R1vasc, Clusters and Compass Points
Objective: Evaluate the technical development and long-term outcomes of Parenchymal-sparing One-Stage Hepatectomy (POSH) for colorectal liver metastases (CLM). Summary Background Data: For multiple bilobar CLM, two-stage hepatectomy (TSH) is suggested, with liver transplant proposed for unresectable cases. In this context, POSH showed effectiveness. Methods: A prospective cohort of patients with ≥4 bilobar CLM (2004-2023) was analyzed using an intention-to-treat approach. POSH patients were classified by surgical margin. The primary endpoint was the technique evolution in terms of complexity, feasibility and indications; secondary endpoints included POSH oncological validity, safety, and survival. Results: Of 407 patients, 388 underwent POSH, 17 TSH. Resection area-to-tumor number ratio improved from 0.67 (2004-2007) to 0.41 (2020-2023, P=0.024), eliminating TSH after 207 POSH cases. Among POSH cases: 105 (27.4%) were R0, 153 (39.9%) R1p (tumor-parenchymal exposure), 37 (9.7%) R1v (tumor-vessel detachment), and 88 (23.0%) R1vp (vascular/parenchymal exposure). R1v had outcomes comparable to R0, while R1p had worse OS, RFS, and local recurrence (PP=0.002), primary tumor nodal status (HR 1.695, P=0.005), and R1p margin (HR 1.481, P=0.024) predicted OS. Major complications occurred in 9.3%, 90-day mortality was 0.8%. Redo-hepatectomy was feasible in 93 of 122 (76.2%) patients with intrahepatic recurrence, providing a significant 5-year OS benefit. Conclusions: POSH is effective for bilobar CLM. Advancements in tumor clustering eliminated the need for TSH even in complex cases. R1v outcomes confirm the validity of vascular detachment.
- 8 August 2025
- Published by Wolters Kluwer Health in Annals of Surgery
From Cherry Picking to R1vasc, Clusters and Compass Points
Objective: Evaluate the technical development and long-term outcomes of Parenchymal-sparing One-Stage Hepatectomy (POSH) for colorectal liver metastases (CLM). Summary Background Data: For multiple bilobar CLM, two-stage hepatectomy (TSH) is suggested, with liver transplant proposed for unresectable cases. In this context, POSH showed effectiveness. Methods: A prospective cohort of patients with ≥4 bilobar CLM (2004-2023) was analyzed using an intention-to-treat approach. POSH patients were classified by surgical margin. The primary endpoint was the technique evolution in terms of complexity, feasibility and indications; secondary endpoints included POSH oncological validity, safety, and survival. Results: Of 407 patients, 388 underwent POSH, 17 TSH. Resection area-to-tumor number ratio improved from 0.67 (2004-2007) to 0.41 (2020-2023, P=0.024), eliminating TSH after 207 POSH cases. Among POSH cases: 105 (27.4%) were R0, 153 (39.9%) R1p (tumor-parenchymal exposure), 37 (9.7%) R1v (tumor-vessel detachment), and 88 (23.0%) R1vp (vascular/parenchymal exposure). R1v had outcomes comparable to R0, while R1p had worse OS, RFS, and local recurrence (PP=0.002), primary tumor nodal status (HR 1.695, P=0.005), and R1p margin (HR 1.481, P=0.024) predicted OS. Major complications occurred in 9.3%, 90-day mortality was 0.8%. Redo-hepatectomy was feasible in 93 of 122 (76.2%) patients with intrahepatic recurrence, providing a significant 5-year OS benefit. Conclusions: POSH is effective for bilobar CLM. Advancements in tumor clustering eliminated the need for TSH even in complex cases. R1v outcomes confirm the validity of vascular detachment.
- 29 March 2023
- Published by Springer Nature in Updates in Surgery
- Vol. 75 (4) , 921-930
Facing adenocarcinoma of distal esophagus and esophagogastric junction: a CROSS versus FLOT propensity score-matched analysis of oncological outcomes in a high-volume institution
Multimodality treatments are the gold standard for advanced resectable gastroesophageal cancer. Neoadjuvant CROSS and perioperative FLOT regimens are adopted for distal esophageal and esophagogastric junction adenocarcinoma (DE/EGJ AC). At present, none of the approaches is clearly superior in the context of a curative-intent multimodal treatment. We analyzed consecutive patients treated with CROSS or FLOT and surgery for DE/EGJ AC between August 2017 and October 2021. Propensity score matching was performed to balance baseline characteristics of patients. The primary endpoint was disease-free survival. Secondary endpoints included overall survival, 90-day morbidity/mortality rates, pathological complete response, margin-negative resection, and pattern of recurrence. Of the 111 patients included, 84 were correctly matched after PSM, 42 in each group. The 2-year DFS rate was 54.2% versus 64.1% in the CROSS and FLOT group, respectively (p = 0.182). Patients in the CROSS group showed a lower number of harvested LN when compared to the FLOT group (29.5 versus 39.0 respectively, p = 0.005). A higher rate of distal nodal recurrence was found in the CROSS group (23.8% versus 4.8%, p = 0.026). Although not significant, the CROSS group showed a trend toward higher rate of isolated distant recurrence (33.3% versus 21.4% respectively, p = 0.328), together with a higher rate of early recurrence (23.8% versus 9.5% respectively, p = 0.062). FLOT and CROSS regimens for DE/EGJ AC offer similar DFS and OS, together with comparable morbidity/mortality rates. CROSS regimen was associated with a higher distant nodal recurrence rate. Results of ongoing randomized clinical trials are awaited.
- 29 March 2023
- Published by Springer Nature in Updates in Surgery
- Vol. 75 (4) , 921-930
Facing adenocarcinoma of distal esophagus and esophagogastric junction: a CROSS versus FLOT propensity score-matched analysis of oncological outcomes in a high-volume institution
Multimodality treatments are the gold standard for advanced resectable gastroesophageal cancer. Neoadjuvant CROSS and perioperative FLOT regimens are adopted for distal esophageal and esophagogastric junction adenocarcinoma (DE/EGJ AC). At present, none of the approaches is clearly superior in the context of a curative-intent multimodal treatment. We analyzed consecutive patients treated with CROSS or FLOT and surgery for DE/EGJ AC between August 2017 and October 2021. Propensity score matching was performed to balance baseline characteristics of patients. The primary endpoint was disease-free survival. Secondary endpoints included overall survival, 90-day morbidity/mortality rates, pathological complete response, margin-negative resection, and pattern of recurrence. Of the 111 patients included, 84 were correctly matched after PSM, 42 in each group. The 2-year DFS rate was 54.2% versus 64.1% in the CROSS and FLOT group, respectively (p = 0.182). Patients in the CROSS group showed a lower number of harvested LN when compared to the FLOT group (29.5 versus 39.0 respectively, p = 0.005). A higher rate of distal nodal recurrence was found in the CROSS group (23.8% versus 4.8%, p = 0.026). Although not significant, the CROSS group showed a trend toward higher rate of isolated distant recurrence (33.3% versus 21.4% respectively, p = 0.328), together with a higher rate of early recurrence (23.8% versus 9.5% respectively, p = 0.062). FLOT and CROSS regimens for DE/EGJ AC offer similar DFS and OS, together with comparable morbidity/mortality rates. CROSS regimen was associated with a higher distant nodal recurrence rate. Results of ongoing randomized clinical trials are awaited.
- Open Access
- 21 March 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1146017
The crossroad between autoimmune disorder, tissue remodeling and cancer of the thyroid: The long pentraxin 3 (PTX3)
Thyroid is at the crossroads of immune dysregulation, tissue remodeling and oncogenesis. Autoimmune disorders, nodular disease and cancer of the thyroid affect a large amount of general population, mainly women. We wondered if there could be a common factor behind three processes (immune dysregulation, tissue remodeling and oncogenesis) that frequently affect, sometimes coexisting, the thyroid gland. The long pentraxin 3 (PTX3) is an essential component of the humoral arm of the innate immune system acting as soluble pattern recognition molecule. The protein is found expressed in a variety of cell types during tissue injury and stress. In addition, PTX3 is produced by neutrophils during maturation in the bone-marrow and is stored in lactoferrin-granules. PTX3 is a regulator of the complement cascade and orchestrates tissue remodeling and repair. Preclinical data and studies in human tumors indicate that PTX3 can act both as an extrinsic oncosuppressor by modulating complement-dependent tumor-promoting inflammation, or as a tumor-promoter molecule, regulating cell invasion and proliferation and epithelial to mesenchymal transition, thus suggesting that this molecule may have different functions on carcinogenesis. The involvement of PTX3 in the regulation of immune responses, tissue remodeling and oncosuppressive processes led us to explore its potential role in the development of thyroid disorders. In this review, we aimed to highlight what is known, at the state of the art, regarding the connection between the long pentraxin 3 and the main thyroid diseases i.e., nodular thyroid disease, thyroid cancer and autoimmune thyroid disorders.
- 21 March 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1146017
Open AccessThe crossroad between autoimmune disorder, tissue remodeling and cancer of the thyroid: The long pentraxin 3 (PTX3)
Thyroid is at the crossroads of immune dysregulation, tissue remodeling and oncogenesis. Autoimmune disorders, nodular disease and cancer of the thyroid affect a large amount of general population, mainly women. We wondered if there could be a common factor behind three processes (immune dysregulation, tissue remodeling and oncogenesis) that frequently affect, sometimes coexisting, the thyroid gland. The long pentraxin 3 (PTX3) is an essential component of the humoral arm of the innate immune system acting as soluble pattern recognition molecule. The protein is found expressed in a variety of cell types during tissue injury and stress. In addition, PTX3 is produced by neutrophils during maturation in the bone-marrow and is stored in lactoferrin-granules. PTX3 is a regulator of the complement cascade and orchestrates tissue remodeling and repair. Preclinical data and studies in human tumors indicate that PTX3 can act both as an extrinsic oncosuppressor by modulating complement-dependent tumor-promoting inflammation, or as a tumor-promoter molecule, regulating cell invasion and proliferation and epithelial to mesenchymal transition, thus suggesting that this molecule may have different functions on carcinogenesis. The involvement of PTX3 in the regulation of immune responses, tissue remodeling and oncosuppressive processes led us to explore its potential role in the development of thyroid disorders. In this review, we aimed to highlight what is known, at the state of the art, regarding the connection between the long pentraxin 3 and the main thyroid diseases i.e., nodular thyroid disease, thyroid cancer and autoimmune thyroid disorders.
- Open Access
- 14 June 2022
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2022 (6) , rjac113
Robotic-assisted resection of pelvic mesorectum lipoma during the COVID-19 pandemic: a case report
Mesorectal lipoma is a rare, usually asymptomatic tumor. The best treatment is R0 resection but the previous literature reports different approaches. Robotic surgery allows for an accurate intervention, with a faster postoperative course, less risk of infection and need for transfusions, a faster return to normal daily activities and the best esthetic result. We describe a case of a 43-year-old female with a large lipoma with dislocation of the vagina, rectum and distal sigmoid colon, potentially malignant, successfully treated by robotic excision, which was safe, effective and well tolerated by the patient.
- 14 June 2022
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2022 (6) , rjac113
Open AccessRobotic-assisted resection of pelvic mesorectum lipoma during the COVID-19 pandemic: a case report
Mesorectal lipoma is a rare, usually asymptomatic tumor. The best treatment is R0 resection but the previous literature reports different approaches. Robotic surgery allows for an accurate intervention, with a faster postoperative course, less risk of infection and need for transfusions, a faster return to normal daily activities and the best esthetic result. We describe a case of a 43-year-old female with a large lipoma with dislocation of the vagina, rectum and distal sigmoid colon, potentially malignant, successfully treated by robotic excision, which was safe, effective and well tolerated by the patient.